SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

OFFICIAL TRUMP (TRUMP) is a cryptocurrency and operates on the Solana platform. OFFICIAL TRUMP has a current supply of 999,998,809.831273 with 281,866,746.118905 in circulation. The last known price of OFFICIAL TRUMP is 1.73532194 USD and is up 9.97 over the last 24 hours. It is currently trading on 744 active market(s) with $259,407,006.57 traded over the last 24 hours. More information can be found at https://gettrumpmemes.com/.

Trump For President

A rebound in the TRUMP meme coin has prompted speculative calls for a pump or short squeeze, while the dominant discussion remains bearish: traders call it a pump-and-dump and point to steep losses among holders. Some remain bullish or say they are accumulating, but no specific confirmed catalyst for the move is apparent.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

An industry observers reported identification of a POET optical engine at Foxconns Hon Hai Tech Day has traders debating whether it signals renewed progress in the existing FIT collaboration. Bulls see it as third-party validation, while skeptics say a demo or ecosystem display does not confirm production shipments, purchase orders, or a new company announcement.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLakes pending FDA decision on whether to accept its sonelokimab application for hidradenitis suppurativaand the review timeline, including possible priority reviewis the main focus. Traders are divided between optimism about the drug and regulatory progress and concern about approval risk, weak share performance, and the costs of commercializing without a partner or buyout.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

AXSM is drawing attention ahead of its Q3 results, with investors focused on Auvelitys growthespecially uptake for Alzheimers agitationand whether sales can support a path to profitability. The sharp share-price decline and managements limited recent commentary have intensified the debate: bulls say prescriptions may be understated by sampling and long-term-care channels, while skeptics question the pace of adoption, spending and commercial execution.

Figma, Inc. is an AI-powered digital design and product development platform. The firm offers tools for teams to collaborate on the entire lifecycle of software creation. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma is drawing attention amid volatile SaaS trading, with traders attributing a sector rebound to reports of possible Workday acquisition talks and short covering. The wider debate remains whether AI will threaten Figmas design business or create new revenue, while some investors point to insider selling as a source of pressure.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to fresh 52-week highs ahead of expected Q3 results has put TGTX in focus, with traders watching BRIUMVIs sales momentum and guidance. Buyout and short-squeeze theories are also circulating, but remain speculation rather than confirmed catalysts.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons strong third-quarter results, which beat expectations on growth led by Dupixent and Eylea HD, have driven a sharp share-price breakout. Traders are largely celebrating the report and bullish options activity, while some note that declining legacy Eylea sales remain a risk to watch.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

OUST is drawing attention amid a sharp, volatile pullback that traders link to weakness in growth and AI stocks, with Q3 earnings expectations adding uncertainty. The community is split between buying the dip on Ousters lidar and Physical AI opportunity and warning that shares could fall further.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs upcoming quarterly report is the main focus, with traders debating whether its guidance can support a stretched valuation amid weakness in AI and technology stocks. Bulls expect continued growth, while bears argue that even a solid report may disappoint if it does not exceed high expectations.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVAs stronger-than-expected quarterly results, including solid same-store sales and guest-traffic growth, fueled a sharp rebound and revived discussion of its store-expansion runway. Bulls see continued growth potential, while skeptics point to the stocks high valuation and pressure on restaurant spending.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BBWI's International Momentum Adds Strength to Its Growth Story

Bath & Body Works is benefiting from strong international demand, higher product shipments and store expansion as it works to restore sustainable growth.

Is Bath & Body Works, Inc. (BBWI) Stock Outpacing Its Retail-Wholesale Peers This Year?

Here is how Bath & Body Works (BBWI) and Five Below (FIVE) have performed compared to their sector so far this year.

Bullish Two Hundred Day Moving Average Cross - BBWI

In trading on Thursday, shares of Bath & Body Works Inc (Symbol: BBWI) crossed above their 200 day moving average of $19.83, changing hands as high as $20.80 per share. Bath & Body Works Inc shares are currently trading up about 9.4% on the day. The chart below shows t...

Zacks.com featured highlights include Cracker Barrel, Best Buy, Beazer Homes USA, Cleveland-Cliffs and Bath & Body Works

Cracker Barrel, Best Buy, Beazer Homes, Cleveland-Cliffs and Bath & Body Works draw broker support amid market uncertainty, with earnings beats and growth initiatives.

5 Stocks Liked by Brokers Amid the Prevalent Uncertain Scenario 

Amid market uncertainty, five broker-favored stocks, CBRL, BBY, BZH, CLF and BBWI, stand out for earnings performance, growth initiatives & favorable valuations.


Bath & Body Works (BBWI) Surges 8.7%: Is This an Indication of Further Gains? (Revised)

Bath & Body Works (BBWI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

BBWI's Product Innovation Supports Pricing as Consumers Seek Value

Bath & Body Works is leaning on upgraded formulas, packaging and new fragrances to support pricing as value-conscious consumers pressure broader sales.

Bath & Body Works (BBWI) Surges 8.7%: Is This an Indication of Further Gains?

Bath & Body Works (BBWI) Down 9.9% Since Last Earnings Report: Can It Rebound?

Bath & Body Works (BBWI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

New Strong Sell Stocks for September 16th

AGCO, BSX and BBWI have been added to the Zacks Rank #5 (Strong Sell) List on September 16th, 2026.

Bath & Body Works, Inc. is a specialty retailers and home to America’s Favorite Fragrances, offering a breadth of exclusive fragrances for the body and home, including the selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap. The company was founded by Leslie Herbert Wexner in 1963 and is headquartered in Columbus, OH.

Bath & Body Works Inc

BBWI Stock Draws Investor Cheer After Upbeat Q1 – But CEO Says Performance Remains Below What The Brand Is Capable Of Delivering

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>The company maintained its full-year 2026 guidance with net sales expected to decline between 4.5% and 2.5%.</li><li>Bath &amp; Body Works Chief Financial Officer Eva Boratto will step down effective June 12 to pursue another professional opportunity.</li><li>The company also expects 2026 adjusted earnings of $2.40 to $2.65 per share and free cash flow of about $600 million.</li></ul>Shares of Bath &amp; Body Works, Inc. (BBWI) rose over 10% premarket on Wednesday after the company reported a strong quarter, but the specialty retailer's chief indicated that performance remains below what the brand should deliver.<a href="https://stocktwits.com/symbol/BBWI">Bath &amp; Body Works</a> reported first-quarter (Q1) net sales of $1.4 billion, beating Wall Street Expectations of $1.36 billion, while adjusted net earnings of $0.32 per share surpassed analysts’ estimate of $0.29, according to the Koyfin data.Despite the Q1 beat, Daniel Heaf, chief executive officer at Bath &amp; Body Works, said, “Our first-quarter results exceeded guidance, but remain below the standard our brand is capable of delivering.”Heaf also added that the&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/05/27/3301747/0/en/bath-body-works-reports-first-quarter-results-exceeding-guidance-and-progress-against-the-consumer-first-formula.html">company</a> has been bolstering its hero categories, modernizing the brand, and expanding its reach. These efforts have begun to resonate with its customers, and the company has seen early proof points as a result.“We believe that the foundation we are building will drive improved performance over time, with the impact expected to build through the balance of 2026 and more meaningfully into 2027,” said Heaf.<h2 class="st-heading-2">BBWI Reiterates 2026 Guidance</h2>Bath &amp; Body Works maintained its full-year 2026 guidance, with net sales expected to decline between 4.5% and 2.5% compared to $7.29 billion in fiscal 2025.The company also expects 2026 adjusted earnings of $2.40 to $2.65 per share and free cash flow of about $600 million. Bath &amp; Body Works did not assume share repurchases or tariff refunds for its guidance projections.&nbsp;For the second quarter, the company forecasts net sales&nbsp;to decline between 3% and 5%&nbsp;and earnings of $0.20&nbsp;to $0.25 per share.<h2 class="st-heading-2">BBWI CFO Departure</h2>The company also announced that Chief Financial Officer Eva Boratto will step down effective June 12 to pursue another professional opportunity.Tom Javitch, a 16-year veteran of Bath &amp; Body Works and former L Brands finance leader, has been appointed interim CFO while the company looks for a new CFO through a leading executive search firm.<h2 class="st-heading-2">What Retail Thinks Of BBWI</h2>On Stocktwits, retail sentiment surrounding the stock has improved to ‘extremely bullish’ from ‘bullish’, while message volume stayed ‘high‘ over the past 24 hours.Shares of&nbsp;Bath &amp; Body Works have declined more than 14% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/mnts-stock-200-dma-fund-raising-spacex-momentum/cZggBamRerG">MNTS Stock Surged Past Its 200-DMA Yesterday – Today’s Pre-Market Jump Proves It Could Be A Conviction Move</a>

 A Bath & Body Works logo is displayed outside one of their stores on March 23, 2025 in San Diego, California. (Photo by Kevin Carter/Getty Images)

Bath & Body Works reported first-quarter net sales of $1.4 billion, beating Wall Street Expectations of $1.36 billion.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$BBWI 

🔥
IMO the $20-$25 analysts price targets looks more realistic now smart money buying today. I like this chart setup. Let’s get that breakout started! Holding shares for potential continuation upwards.

Barry Allen

$BBWI What 4 Stars looks like. Here is one that is green, data from 1 week ago when price was $17.34 
 
I told you I am exclusively using this to test it with my own money.  I built it, I know it, and its the only way - have skin in my own game. 
 
EDUCATE!: 
3.5 Stars Game On, 4.0 Stars Game Ready!!, and so on and so on... 
Remember, early is key and this was 17 bucks at OPEN last Monday when I came across this.

🐺 WOLFIE

$BBWI $21 is a real barrier.  If it can get past that, maybe we can even see a PE of 6.  A guy can dream.

Lee Reynolds

Despite the rough close to the week, -3%, $BBWI is still holding above the breakout level of $19.50 (50WMA)! 
 
A continuation / entry occurs at a break of $22.75

Feed

News

Sentiment

Earnings

Fundamentals

Info

BBWI Bath & Body Works Inc

Fundamentals

Latest BBWI News